Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Inducible Nitric Oxide Synthase
100%
Ovine
100%
Acute Lung Injury
100%
Airway Obstruction
100%
Neuronal Nitric Oxide Synthase (nNOS)
100%
Nitric Oxide Synthase Inhibition
100%
Vascular Endothelial Growth Factor
66%
Lung
66%
Sheep
66%
Sham
66%
Lung Tissue
66%
Lung Edema
66%
3-nitrotyrosine (3-NT)
66%
Pulmonary Dysfunction
33%
Sepsis
33%
Nitric Oxide
33%
Injured Patients
33%
Pneumonia
33%
Pseudomonas Aeruginosa (P. aeruginosa)
33%
Disease Process
33%
Effective Treatment
33%
Nitrosative Stress
33%
Potential Gains
33%
Edema Formation
33%
Treatment Regimen
33%
Mechanically Ventilated
33%
Baseline Measurements
33%
Research Laboratories
33%
Adult Female
33%
Continuous Infusion
33%
Adenosine Diphosphate Ribose
33%
Polyadenosine
33%
Cotton
33%
Ribose
33%
Pulmonary Gas Exchange
33%
Neuronal Nitric Oxide Synthase Inhibitor
33%
Specific Inhibition
33%
University Research
33%
7-nitroindazole
33%
Controlled Randomized Trial
33%
Inducible Nitric Oxide Synthase Inhibitor
33%
Medicine and Dentistry
Inducible Nitric Oxide Synthase
100%
Acute Lung Injury
100%
Neuronal Nitric Oxide Synthase
100%
Lung
100%
Airway Obstruction
75%
Vasculotropin
50%
Pulmonary Edema
50%
Nitric Oxide Synthase Inhibitor
50%
3 Nitrotyrosine
50%
Pathophysiology
25%
Sepsis
25%
Nitric Oxide
25%
Infusion
25%
Pseudomonas aeruginosa
25%
Poly(adenosine Diphosphate Ribose)
25%
Disease Process
25%
Morbidity
25%
Randomized Controlled Trial
25%
Continuous Infusion
25%
Breathing
25%
Ribose
25%
Lung Gas Exchange
25%
Nitrosative Stress
25%
7-Nitroindazole
25%
Effective Treatment
25%
Pneumonia
25%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lung Injury
100%
Inducible Nitric Oxide Synthase
100%
Neuronal Nitric Oxide Synthase
100%
Airway Obstruction
75%
Vasculotropin
50%
Nitric Oxide Synthase Inhibitor
50%
Lung Edema
50%
3 Nitrotyrosine
50%
Pathophysiology
25%
Sheep
25%
Nitric Oxide
25%
Pseudomonas aeruginosa
25%
Sepsis
25%
Poly(adenosine Diphosphate Ribose)
25%
Morbidity
25%
Randomized Controlled Trial
25%
Ribose
25%
7 Nitroindazole
25%
Diseases
25%
Pneumonia
25%